← Leaderboards
Swati S More
University Of Minnesota
$4,256,281
Attributed
$6,587,561
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,587,561 · 3
By mechanism
R01$6,587,561 · 3
Top collaborators
- Patrick Rothwell7 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Patrick Rothwell$8,678,718
- Fang Li$9,155,528
- Emilia M Lefevre$827,130
- Brian Hong Trieu$152,464
- Areef Ishani$1,902,699
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposCellsNeuronsBrainExtracellularDrug KineticsLeadPreventIn VitroNovel TherapeuticsPathway InteractionsToxic EffectAttenuatedAffectProteinsPharmaceutical PreparationsPharmaceutical ChemistryProdrugsMetabolismEndogenous OpioidsGlutamatesDopamine ReceptorEnzyme InhibitionIntravenous
Grant awards (12)
Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme$561,759
R01 · FY2025 · DA · contact PI
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders$532,385
R01 · FY2025 · DA
Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme$571,020
R01 · FY2024 · DA · contact PI
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders$56,500
R01 · FY2024 · DA
Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme$580,098
R01 · FY2023 · DA · contact PI
Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy$385,000
R01 · FY2023 · AG · contact PI
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders$1,771,799
R01 · FY2022 · DA
Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme$589,000
R01 · FY2022 · DA · contact PI
Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy$385,000
R01 · FY2022 · AG · contact PI
Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy$385,000
R01 · FY2021 · AG · contact PI
Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy$385,000
R01 · FY2020 · AG · contact PI
Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy$385,000
R01 · FY2019 · AG · contact PI